Explain me the difference and function of uptake 1 and uptake 2 transporter
Reading File
Finding Sources
Finding Sources
Searching the Web
uptake 1 uptake 2 transporter norepinephrine pharmacology difference
Reading File
Reading File
Reading File
Loading Image
Finding Sources
I now have all the information needed for a comprehensive answer. Here is the full response:
Uptake 1 vs. Uptake 2 Transporters
These are the two carrier-mediated systems that terminate catecholamine action at the synapse. Together they account for the rapid removal of norepinephrine (NE) and epinephrine (EPI) after release, far faster than enzymatic degradation alone.
In the diagram: step 6 = Uptake 1 (neuronal reuptake), step 7 = Uptake 2 (extraneuronal uptake into effector cell), step 8 = systemic overflow.
Uptake 1 - The Norepinephrine Transporter (NET)
| Feature | Detail |
|---|---|
| Modern name | Norepinephrine Transporter (NET) |
| Gene | SLC6A2 |
| Location | Presynaptic adrenergic nerve terminal membrane |
| Mechanism | Active, Na+/Cl- cotransport (energy-dependent, temperature-dependent, stereospecific) |
| Substrate preference | NE > EPI >> isoproterenol (isoproterenol is NOT a substrate) |
| Affinity | HIGH affinity for NE (low Km) |
| Capacity (Vmax) | Lower than Uptake 2 |
| Fate of recaptured NE | Stored back into vesicles (via VMAT2) for reuse, or deaminated by intraneuronal MAO |
| Physiological importance | Accounts for ~80-90% of NE removal from the synapse |
Function: After NE is released into the synaptic cleft, NET rapidly pumps it back into the presynaptic neuron. This is the dominant pathway for terminating NE action. It conserves transmitter for reuse and tightly controls the duration and intensity of sympathetic signaling. NET belongs to the SLC6 family alongside DAT (dopamine transporter, SLC6A3) and SERT (serotonin transporter, SLC6A4).
Blockers of Uptake 1:
- Cocaine - blocks NET (and DAT/SERT), prolonging catecholamine action
- Tricyclic antidepressants (TCAs) (e.g., imipramine) - NET/SERT blockade
- Phenothiazines
- Amphetamines - also reverse NET to release NE outward
- Guanethidine - transported INTO the neuron by NET; this is required for its antihypertensive action
- SNRIs/NRIs (e.g., venlafaxine, reboxetine)
Uptake 2 - The Extraneuronal Transporter (ENT) / OCT3
| Feature | Detail |
|---|---|
| Modern name | Extraneuronal Transporter (ENT); Organic Cation Transporter 3 (OCT3) |
| Gene | SLC22A3 |
| Location | Extraneuronal / non-neuronal cells: smooth muscle, cardiac muscle, glia, liver, kidney, placenta |
| Mechanism | Passive, facilitated diffusion - moves organic cations DOWN their electrochemical gradient; NOT Na+-dependent |
| Substrate preference | EPI > NE > DA; also 5-HT, histamine, choline, spermine, guanidine, creatinine |
| Affinity | LOW affinity (high Km) |
| Capacity (Vmax) | HIGHER than Uptake 1 |
| Fate of recaptured NE | Metabolized by MAO + COMT to form vanillylmandelic acid (VMA) |
| Physiological importance | Minor contributor to NE termination; more relevant for EPI and circulating catecholamines |
Function: ENT/OCT3 takes up catecholamines into the effraneuronal tissues surrounding the synapse. Because it has LOW affinity but HIGH capacity, it becomes more relevant when catecholamine concentrations are high (e.g., stress, pheochromocytoma, exogenous catecholamine infusions). NE taken up here is not recycled - it is irreversibly metabolized. OCT3 also transports a broader range of organic cations beyond catecholamines, and its activity is regulated by MAPK and Ca2+-calmodulin signaling.
Blockers of Uptake 2:
- Corticosteroids (hydrocortisone, dexamethasone) - important clinical point: steroids potentiate catecholamine effects partly by blocking Uptake 2
- Normetanephrine and O-methylated catecholamines
- Phenoxybenzamine (at high doses)
Side-by-Side Comparison
| Property | Uptake 1 (NET) | Uptake 2 (ENT/OCT3) |
|---|---|---|
| Location | Presynaptic neuron | Extraneuronal cells (muscle, glia, organs) |
| Affinity | High (low Km) | Low (high Km) |
| Capacity | Low Vmax | High Vmax |
| Energy | Active (Na+-dependent) | Passive (Na+-independent) |
| Substrate preference | NE > EPI | EPI > NE |
| Isoproterenol transport? | No | No |
| Fate of substrate | Recycled into vesicles or MAO | MAO + COMT degradation |
| Predominance | Dominant pathway (~80-90%) | Minor pathway (~5%) |
| Blocked by | Cocaine, TCAs, amphetamines, SNRIs | Corticosteroids, normetanephrine |
Clinical Pearls
- Cocaine and TCAs block Uptake 1, causing accumulation of NE in the synapse - this explains the hypertension, tachycardia, and potentiation of vasopressors seen with these agents.
- Corticosteroids block Uptake 2, which is one reason they potentiate the pressor response to catecholamines. Patients on steroids may show enhanced and prolonged responses to exogenous epinephrine or norepinephrine.
- Exogenous catecholamines given systemically (e.g., IV epinephrine) are cleared primarily by the liver and kidney (MAO/COMT), not Uptake 1, explaining their longer duration of action compared to endogenous neurally-released NE.
- Guanethidine is a classic pharmacology teaching example: it requires Uptake 1 (NET) to enter the neuron, so drugs that block NET (like TCAs) will also block guanethidine's antihypertensive effect.
Sources: Goodman & Gilman's Pharmacological Basis of Therapeutics, p. 211; Goldman-Cecil Medicine; Barash Clinical Anesthesia, p. 1045-1047
Explain me the difference and function of uptake 1 and uptake 2 transporter
I already covered this topic in detail just a moment ago! Here's a concise summary, and the full answer is right above in our conversation.
Uptake 1 vs. Uptake 2 - Quick Reference
These are the two carrier-mediated systems that remove catecholamines (mainly norepinephrine/NE) from the synapse after release.
Uptake 1 - Norepinephrine Transporter (NET, SLC6A2)
- Location: Presynaptic adrenergic nerve terminal
- Mechanism: Active transport, Na+/Cl- dependent (energy-requiring)
- Affinity: HIGH for NE (NE > EPI; isoproterenol not transported)
- Capacity: Lower Vmax
- Fate of NE: Recycled back into storage vesicles (via VMAT2) or broken down by intraneuronal MAO
- Importance: Dominant pathway - removes ~80-90% of synaptically released NE
- Blocked by: Cocaine, tricyclic antidepressants, amphetamines, SNRIs/NRIs
Uptake 2 - Extraneuronal Transporter (ENT / OCT3, SLC22A3)
- Location: Non-neuronal cells - smooth muscle, cardiac muscle, glia, liver, kidney
- Mechanism: Passive facilitated diffusion, NOT Na+-dependent
- Affinity: LOW for catecholamines (EPI > NE > DA)
- Capacity: Higher Vmax (kicks in at high catecholamine concentrations)
- Fate of NE: Irreversibly metabolized by MAO + COMT → vanillylmandelic acid (VMA)
- Importance: Minor pathway (~5%), more relevant for circulating/exogenous catecholamines
- Blocked by: Corticosteroids (clinically important!), normetanephrine
Key Comparison Table
| Property | Uptake 1 (NET) | Uptake 2 (OCT3) |
|---|---|---|
| Location | Presynaptic neuron | Extraneuronal tissues |
| Affinity | High (low Km) | Low (high Km) |
| Capacity | Low Vmax | High Vmax |
| Na+-dependent? | Yes | No |
| Substrate preference | NE > EPI | EPI > NE |
| Fate of substrate | Recycled or MAO | MAO + COMT degradation |
| % of NE removed | ~80-90% | ~5% |
| Blocked by | Cocaine, TCAs | Corticosteroids |
Clinical Pearls
- Cocaine / TCAs block Uptake 1 → NE accumulates in synapse → hypertension, tachycardia, potentiated vasopressor response
- Corticosteroids block Uptake 2 → enhanced and prolonged pressor response to epinephrine/norepinephrine
- Guanethidine must be transported INTO the neuron via Uptake 1 to work; TCAs therefore block its antihypertensive effect
- Exogenous IV catecholamines bypass Uptake 1 and are cleared by liver/kidney MAO+COMT, giving them a longer duration than endogenously released NE
Sources: Goodman & Gilman's Pharmacological Basis of Therapeutics; Goldman-Cecil Medicine; Barash's Clinical Anesthesia
What is function of uptake 1 and uptake 2
Both transporters serve the same broad purpose: terminating the action of catecholamines (mainly norepinephrine/NE) after they are released into the synapse. They do this through different mechanisms and at different locations.
Uptake 1 (NET - Norepinephrine Transporter)
Primary function: Recycle NE back into the presynaptic neuron
After NE is released into the synaptic cleft, NET pumps it back into the nerve terminal. This serves two goals:
- Terminates synaptic transmission - rapidly clears NE from the cleft, ending its receptor stimulation
- Conserves transmitter - recycled NE is repackaged into vesicles (via VMAT2) for future release, so the neuron doesn't run out during prolonged stimulation
This is the dominant removal pathway, handling ~80-90% of all synaptically released NE.
Uptake 2 (ENT/OCT3 - Extraneuronal Transporter)
Primary function: Mop up overflow NE in surrounding non-neuronal tissues
NE that escapes the synaptic cleft is taken up by surrounding effector cells (smooth muscle, cardiac muscle, glia, liver). Unlike Uptake 1, the NE captured here is not recycled - it is permanently degraded by MAO + COMT into vanillylmandelic acid (VMA).
This serves two goals:
- Prevents spillover - limits how much NE diffuses away from the synapse into the circulation
- Fine-tunes tissue response - by degrading catecholamines locally, it acts as a buffer against excessive receptor stimulation
This is a minor pathway (~5%), but becomes more relevant when catecholamine levels are very high (e.g., stress, pheochromocytoma, IV catecholamine infusions).
In One Sentence Each
- Uptake 1: Pulls NE back into the neuron that released it, for reuse - the main "off switch" for sympathetic transmission.
- Uptake 2: Pulls NE into surrounding non-neuronal cells, where it is destroyed - a secondary cleanup system.
This is a shared conversation. Sign in to Orris to start your own chat.